| Dr Kelley W Sullivan, MD | |
|
2002 Medical Pkwy, Ste 500, Annapolis, MD 21401-3046 | |
| (410) 573-6480 | |
| (410) 573-9413 |
| Full Name | Dr Kelley W Sullivan |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 36 Years |
| Location | 2002 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497762348 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D41534 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Umd Shore Medical Center At Easton | Easton, MD | Hospital |
| Medstar Washington Hospital Center | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capitol Cardiologic, Llp | 0042226201 | 13 |
| Cardiology Associates Llc | 5092990952 | 63 |
News Archive
The Centers for Medicare & Medicaid Services (CMS) today proposed to expand coverage of implantable cardioverter defibrillators (ICDs), a move expected to save thousands of lives a year.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
MMR Information Systems, Inc., which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that its unaudited revenue for the nine month period ended September 30, 2009 reflected an increase of 64% from the comparable period in 2008.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
› Verified 1 days ago
| Entity Name | Capitol Cardiologic, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427109776 PECOS PAC ID: 0042226201 Enrollment ID: O20060224000257 |
News Archive
The Centers for Medicare & Medicaid Services (CMS) today proposed to expand coverage of implantable cardioverter defibrillators (ICDs), a move expected to save thousands of lives a year.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
MMR Information Systems, Inc., which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that its unaudited revenue for the nine month period ended September 30, 2009 reflected an increase of 64% from the comparable period in 2008.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
› Verified 1 days ago
| Entity Name | Cardiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396042719 PECOS PAC ID: 5092990952 Enrollment ID: O20110523000017 |
News Archive
The Centers for Medicare & Medicaid Services (CMS) today proposed to expand coverage of implantable cardioverter defibrillators (ICDs), a move expected to save thousands of lives a year.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
MMR Information Systems, Inc., which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that its unaudited revenue for the nine month period ended September 30, 2009 reflected an increase of 64% from the comparable period in 2008.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
› Verified 1 days ago
| Entity Name | Medstar Heart Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528345378 PECOS PAC ID: 5698932960 Enrollment ID: O20160226000452 |
News Archive
The Centers for Medicare & Medicaid Services (CMS) today proposed to expand coverage of implantable cardioverter defibrillators (ICDs), a move expected to save thousands of lives a year.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
MMR Information Systems, Inc., which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that its unaudited revenue for the nine month period ended September 30, 2009 reflected an increase of 64% from the comparable period in 2008.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kelley W Sullivan, MD 106 Irving St Nw, Ste 2700n, Washington, DC 20010-2927 Ph: (202) 723-5524 | Dr Kelley W Sullivan, MD 2002 Medical Pkwy, Ste 500, Annapolis, MD 21401-3046 Ph: (410) 573-6480 |
News Archive
The Centers for Medicare & Medicaid Services (CMS) today proposed to expand coverage of implantable cardioverter defibrillators (ICDs), a move expected to save thousands of lives a year.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
MMR Information Systems, Inc., which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), today announced that its unaudited revenue for the nine month period ended September 30, 2009 reflected an increase of 64% from the comparable period in 2008.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
› Verified 1 days ago
Gashaw Adugna Dadi, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 240-495-4189 | |
Dr. Eugene Thomas Manion, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 900 Bestgate Road, Suite 303, Annapolis, MD 21401 Phone: 410-224-8220 Fax: 410-841-2482 | |
Dr. Lisa A Dimarzio, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Parkway, Suite 100, Annapolis, MD 21401 Phone: 410-573-1110 Fax: 410-266-0714 | |
Dr. Richard A Bernstein, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 133 Defense Hwy, Suite 109, Annapolis, MD 21401 Phone: 401-224-5558 Fax: 410-224-7321 | |
Dr. Jonathan A Altschuler, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Ste 500, Annapolis, MD 21401 Phone: 410-573-6480 Fax: 410-573-9413 | |
Dr. Ira M Weinstein, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy, Suite 607, Annapolis, MD 21401 Phone: 410-266-1644 Fax: 410-266-1642 | |
Dr. James M Blake, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 820 Bestgate Road, Suite 2a, Annapolis, MD 21401 Phone: 410-224-2116 Fax: 410-224-2118 |